Metformin Zentiva (Metformin Hydrochloride)

Metformin Hydrochloride lowers blood sugar primarily by inhibiting gluconeogenesis in the liver and enhancing peripheral uptake of glucose. It activates AMP‑activated protein kinase (AMPK), which regulates energy balance and contributes to reduced hepatic glucose production and improved insulin sensitivity.

The appropriate dose of Metformin Zentiva is determined by the prescribing healthcare professional based on individual factors such as renal function, age, and glycemic response. Dosage adjustments are made to achieve optimal blood glucose control while minimizing side effects.

Safety of Metformin Zentiva in pregnancy or while breastfeeding should be evaluated by a qualified clinician. The drug may be used when the potential benefit outweighs any possible risk to the fetus or infant, and decisions are made on a case‑by‑case basis.

To order Metformin Zentiva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metformin Zentiva belongs to the biguanide class and is often first‑line therapy for type 2 diabetes because of its efficacy, low risk of hypoglycemia, and favorable impact on weight. Compared with sulfonylureas or insulin, it does not cause significant weight gain and has a distinct mechanism targeting hepatic glucose production.

Metformin Zentiva should be stored at temperatures below 25 °C in its original container, protected from moisture and direct sunlight. Keep the product out of reach of children and avoid exposure to excessive humidity, which could affect tablet integrity.

Metformin Zentiva is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablets are swallowed whole with a full glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider and not alter the regimen without medical advice.

The most serious risk is lactic acidosis, a rare but life‑threatening condition that can occur in patients with severe renal impairment, hepatic disease, or excessive alcohol intake. Other serious concerns include severe skin reactions such as Stevens‑Johnson syndrome and significant liver injury.

Metformin Zentiva is contraindicated in individuals with known hypersensitivity to metformin, severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, including diabetic ketoacidosis, and in patients with severe liver disease. Clinicians should assess each patient’s medical history before initiating therapy.